Aarti Pharmalabs Share Price
885.10+38.65 (+4.57%)
-4.85% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
AARTIPHARMNSE
Aarti Pharmalabs Share Price
885.10+38.65 (+4.57%)
-4.85% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | -2% | -14% |
| - | - | -3% | -36% |
| - | - | 25% | -9% |
| 11% | 14% | 12% | 9% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
AARTIPHARM
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,846.8 | ₹448196 Cr | 37.05 | 12.07 | 62.82 | ₹11479 Cr |
| 9,333 | ₹250390 Cr | 85.6 | 34.04 | 128.41 | ₹2568 Cr |
| 4,914.5 | ₹188967 Cr | 86.64 | 16.72 | 97.06 | ₹2163 Cr |
| 1,163.7 | ₹115860 Cr | 25.67 | 9.42 | 62.53 | ₹5040 Cr |
| 1,381.2 | ₹111888 Cr | 33.19 | 9.77 | 57.87 | ₹3879 Cr |
| 2,003.1 | ₹109035 Cr | 99.72 | 6.8 | 29.25 | ₹889 Cr |
| 2,486.6 | ₹100364 Cr | 49.13 | 13.75 | 71.08 | ₹1913 Cr |
| 1,209.7 | ₹100329 Cr | 31.14 | 5.32 | 63.99 | ₹4196 Cr |
| 1,695.8 | ₹98804 Cr | 26.61 | 17.95 | 96.84 | ₹3505 Cr |
| 2,115.8 | ₹96940 Cr | 17.53 | 30.95 | 154.36 | ₹5333 Cr |
| 885.1 | ₹7676 Cr | 36.01 | 8.4 | 35.81 | ₹175 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹536 Cr | ₹583 Cr | ₹432 Cr | ₹418 Cr | ₹386 Cr | ₹564 Cr | ₹538 Cr | ₹458 Cr | ₹555 Cr | ₹506 Cr | ₹449 Cr | ₹440 Cr | ₹458 Cr | ₹485 Cr | ₹472 Cr | ₹531 Cr | ₹457 Cr | ₹460 Cr |
| ₹45 L | ₹8 Cr | -₹37 L | ₹5 L | ₹77 L | ₹86 L | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹99 L | ₹48 L | ₹74 L | ₹29 L | ₹1 Cr | ₹2 L | ₹3 Cr |
| ₹536 Cr | ₹591 Cr | ₹432 Cr | ₹418 Cr | ₹387 Cr | ₹565 Cr | ₹543 Cr | ₹463 Cr | ₹558 Cr | ₹508 Cr | ₹450 Cr | ₹441 Cr | ₹459 Cr | ₹486 Cr | ₹472 Cr | ₹532 Cr | ₹457 Cr | ₹463 Cr |
| ₹430 Cr | ₹498 Cr | ₹359 Cr | ₹368 Cr | ₹318 Cr | ₹443 Cr | ₹432 Cr | ₹385 Cr | ₹479 Cr | ₹407 Cr | ₹372 Cr | ₹370 Cr | ₹391 Cr | ₹421 Cr | ₹402 Cr | ₹458 Cr | ₹385 Cr | ₹399 Cr |
| ₹137 Cr | ₹121 Cr | ₹102 Cr | ₹75 Cr | ₹92 Cr | ₹144 Cr | ₹134 Cr | ₹98 Cr | ₹99 Cr | ₹120 Cr | ₹97 Cr | ₹89 Cr | ₹85 Cr | ₹81 Cr | ₹87 Cr | ₹91 Cr | ₹86 Cr | ₹78 Cr |
| ₹13 Cr | ₹17 Cr | ₹13 Cr | ₹11 Cr | ₹7 Cr | ₹7 Cr | ₹10 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr | ₹5 Cr |
| ₹94 Cr | ₹76 Cr | ₹58 Cr | ₹39 Cr | ₹63 Cr | ₹115 Cr | ₹101 Cr | ₹72 Cr | ₹74 Cr | ₹96 Cr | ₹74 Cr | ₹67 Cr | ₹64 Cr | ₹59 Cr | ₹65 Cr | ₹69 Cr | ₹68 Cr | ₹59 Cr |
| ₹69 Cr | ₹56 Cr | ₹43 Cr | ₹29 Cr | ₹48 Cr | ₹88 Cr | ₹74 Cr | ₹55 Cr | ₹55 Cr | ₹65 Cr | ₹53 Cr | ₹52 Cr | ₹47 Cr | ₹43 Cr | ₹48 Cr | ₹51 Cr | ₹52 Cr | ₹49 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| — | — | — | — | — | — |
| ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹25 L | ₹25 L |
| ₹3 Cr | ₹2 Cr | ₹23 L | ₹0 | ₹45 Cr | ₹0 |
| ₹2076 Cr | ₹1943 Cr | ₹1712 Cr | ₹1513 Cr | ₹1341 Cr | -₹2 L |
| ₹2076 Cr | ₹1943 Cr | ₹1712 Cr | ₹1513 Cr | ₹1341 Cr | -₹2 L |
| ₹2125 Cr | ₹1990 Cr | ₹1757 Cr | ₹1558 Cr | ₹1386 Cr | ₹23 L |
| ₹186 Cr | ₹104 Cr | ₹4 L | ₹18 L | ₹55 L | ₹0 |
| ₹134 Cr | ₹128 Cr | ₹108 Cr | ₹79 Cr | ₹71 Cr | ₹0 |
| ₹92 Cr | ₹19 Cr | ₹17 Cr | ₹53 L | ₹2 Cr | ₹0 |
| ₹8 Cr | ₹8 Cr | ₹6 Cr | ₹5 Cr | ₹0 | ₹0 |
| ₹420 Cr | ₹259 Cr | ₹131 Cr | ₹85 Cr | ₹73 Cr | ₹0 |
| — | — | — | — | — | — |
| ₹335 Cr | ₹278 Cr | ₹378 Cr | ₹340 Cr | ₹215 Cr | ₹26,000 |
| ₹135 Cr | ₹70 Cr | ₹46 Cr | ₹38 Cr | ₹12 Cr | ₹20,000 |
| ₹457 Cr | ₹293 Cr | ₹264 Cr | ₹214 Cr | ₹338 Cr | ₹2 L |
| ₹11 Cr | ₹13 Cr | ₹6 Cr | ₹9 Cr | ₹16 Cr | ₹0 |
| ₹938 Cr | ₹653 Cr | ₹694 Cr | ₹601 Cr | ₹581 Cr | ₹2 L |
| ₹3482 Cr | ₹2902 Cr | ₹2582 Cr | ₹2244 Cr | ₹2040 Cr | ₹25 L |
| ₹8 Cr | ₹14 Cr | ₹7 Cr | ₹7 Cr | ₹0 | ₹0 |
| ₹686 Cr | ₹396 Cr | ₹264 Cr | ₹214 Cr | ₹339 Cr | ₹2 L |
| — | — | — | — | — | — |
| ₹2135 Cr | ₹1796 Cr | ₹1609 Cr | ₹1431 Cr | ₹1225 Cr | ₹0 |
| ₹697 Cr | ₹659 Cr | ₹576 Cr | ₹505 Cr | ₹443 Cr | ₹0 |
| ₹1437 Cr | ₹1137 Cr | ₹1033 Cr | ₹926 Cr | ₹782 Cr | ₹0 |
| ₹305 Cr | ₹307 Cr | ₹78 Cr | ₹62 Cr | ₹165 Cr | ₹0 |
| ₹194 Cr | ₹29 Cr | ₹37 Cr | ₹36 Cr | ₹32 Cr | ₹0 |
| ₹194 Cr | ₹29 Cr | ₹37 Cr | ₹36 Cr | ₹32 Cr | ₹0 |
| ₹60 Cr | ₹44 Cr | ₹29 Cr | ₹18 Cr | ₹10 Cr | ₹0 |
| ₹2084 Cr | ₹1584 Cr | ₹1236 Cr | ₹1081 Cr | ₹1012 Cr | ₹0 |
| — | — | — | — | — | — |
| ₹0 | ₹48 Cr | ₹70 Cr | ₹51 Cr | ₹0 | ₹0 |
| ₹640 Cr | ₹588 Cr | ₹643 Cr | ₹602 Cr | ₹475 Cr | ₹0 |
| ₹583 Cr | ₹575 Cr | ₹519 Cr | ₹450 Cr | ₹377 Cr | ₹0 |
| ₹10 Cr | ₹9 Cr | ₹24 Cr | ₹12 Cr | ₹83 Cr | ₹25 L |
| ₹12 Cr | ₹12 Cr | ₹17 Cr | ₹8 Cr | ₹11 Cr | ₹0 |
| ₹152 Cr | ₹87 Cr | ₹72 Cr | ₹40 Cr | ₹82 Cr | ₹0 |
| ₹1397 Cr | ₹1318 Cr | ₹1346 Cr | ₹1163 Cr | ₹1028 Cr | ₹25 L |
| ₹460 Cr | ₹665 Cr | ₹651 Cr | ₹562 Cr | ₹447 Cr | ₹23 L |
| ₹3482 Cr | ₹2902 Cr | ₹2582 Cr | ₹2244 Cr | ₹2040 Cr | ₹25 L |
| ₹234 | ₹219 | ₹194 | ₹172 | ₹53,647 | ₹9 |
| ₹234 | ₹219 | ₹194 | ₹172 | ₹53,647 | ₹9 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| ₹228 Cr | ₹361 Cr | ₹300 Cr | ₹261 Cr | ₹155 Cr | -₹46,000 |
| ₹188 Cr | ₹120 Cr | ₹95 Cr | ₹83 Cr | ₹52 Cr | ₹0 |
| -₹107 Cr | -₹86 Cr | -₹122 Cr | -₹32 Cr | -₹230 Cr | ₹46,000 |
| ₹309 Cr | ₹395 Cr | ₹273 Cr | ₹312 Cr | -₹23 Cr | ₹0 |
| ₹262 Cr | ₹330 Cr | ₹216 Cr | ₹250 Cr | -₹44 Cr | ₹0 |
| -₹431 Cr | -₹412 Cr | -₹215 Cr | -₹158 Cr | -₹139 Cr | ₹0 |
| ₹171 Cr | ₹65 Cr | ₹10 Cr | -₹163 Cr | ₹260 Cr | ₹0 |
| ₹2 Cr | -₹17 Cr | ₹12 Cr | -₹71 Cr | ₹78 Cr | ₹0 |
| ₹7 Cr | ₹24 Cr | ₹12 Cr | ₹83 Cr | ₹5 Cr | ₹25 L |
| ₹9 Cr | ₹7 Cr | ₹24 Cr | ₹12 Cr | ₹83 Cr | ₹25 L |
Fundamental Ratios
Consolidated
Standalone
No results found
Aarti Pharmalabs Share Price
885.10+38.65 (+4.57%)
-4.85% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 4
Bearish signals: 5 out of 9 oscillators
RSI
63.02Buy
STOCH %K
83.11Sell
MACD Level(12,26)
12.48Buy
Ultimate Oscillator
49.88Sell
Aroon Oscillator
14.00Sell
BOP
0.48Buy
CCI
145.50Sell
Williams %R
-16.89Sell
Momentum
19.90Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
841.28Buy
SMA 9
829.30Buy
EMA 21
832.87Buy
SMA 21
841.29Buy
EMA 50
797.62Buy
SMA 50
785.50Buy
EMA 200
752.21Buy
SMA 200
727.09Buy
WMA 20
839.84Buy
Pivot
Pivot
Classic
Resistance 5
1082.95
Resistance 4
1022.95
Resistance 3
962.95
Resistance 2
902.95
Resistance 1
874.70
Pivot
842.95
Support 1
814.70
Support 2
782.95
Support 3
722.95
Support 4
662.95
Support 5
602.95
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Aarti Pharmalabs Share Price
885.10+38.65 (+4.57%)
-4.85% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 42.86% | 43.08% | 43.10% | 42.88% | 43.72% | 44.29% |
| 8.17% | 8.39% | 7.68% | 8.02% | 7.34% | 7.36% |
| 6.42% | 6.60% | 6.57% | 6.16% | 6.90% | 6.74% |
| 0.79% | 0.80% | 1.09% | 0.79% | 0.90% | 0.78% |
| 41.76% | 41.13% | 41.56% | 42.15% | 41.14% | 40.83% |
Bulk & block deals
Name
Unifi Capital Private Limited
Jasmine Family Trust
Microcurves Trading Private Limited
Nk Securities Research Private Limited
Qe Securities Llp
Junomoneta Finsol Private Limited
Microcurves Trading Private Limited
Nk Securities Research Private Limited
Qe Securities Llp
Junomoneta Finsol Private Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 21 Sep 2026 | Purchase | 75.03 Cr | ₹820 | 9.15 L | Bulk | 1.009045 | NSE |
| 18 Sep 2026 | Sell | 51.46 Cr | ₹820.02 | 6.28 L | Bulk | 0.691995 | NSE |
| 11 Aug 2026 | Purchase | 64.82 Cr | ₹903.94 | 7.17 L | Bulk | 0.790725 | NSE |
| 11 Aug 2026 | Purchase | 57.85 Cr | ₹903.39 | 6.40 L | Bulk | 0.706239 | NSE |
| 11 Aug 2026 | Purchase | 51.88 Cr | ₹899.52 | 5.77 L | Bulk | 0.636026 | NSE |
| 11 Aug 2026 | Purchase | 41.29 Cr | ₹901.69 | 4.58 L | Bulk | 0.505008 | NSE |
| 11 Aug 2026 | Sell | 64.84 Cr | ₹904.35 | 7.17 L | Bulk | 0.790725 | NSE |
| 11 Aug 2026 | Sell | 57.90 Cr | ₹903.73 | 6.41 L | Bulk | 0.7065 | NSE |
| 11 Aug 2026 | Sell | 51.43 Cr | ₹902.18 | 5.70 L | Bulk | 0.628595 | NSE |
| 11 Aug 2026 | Sell | 41.10 Cr | ₹902.03 | 4.56 L | Bulk | 0.502494 | NSE |
Insider trading & SAST
Client name
Relacion Trusteeship Services Private Limited
Safechem Enterprises Private Limited
Safechem Enterprises Private Limited
Safechem Enterprises Private Limited
Safechem Enterprises Private Limited
Nikhil Parimal Desai
Nikhil Parimal Desai
Safechem Enterprises Private Limited
Safechem Enterprises Private Limited
Safechem Enterprises Private Limited
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 09 Sep 2026 | Promoter Group | Disposal | 0.066167 | 0.69 | 5.23 Cr | ₹871.08 | 60 K | 08 Sep 2026 - 09 Sep 2026 | Market Sale | 6,27,500 | Insider Trading | — | Equity |
| 09 Sep 2026 | Promoter Group | Disposal | 0.065505 | 0.4 | 5.20 Cr | ₹875.17 | 59.40 K | 07 Sep 2026 - 08 Sep 2026 | Market Sale | 3,65,750 | Insider Trading | — | Equity |
| 07 Sep 2026 | Promoter Group | Disposal | 0.033083 | 0.47 | 2.59 Cr | ₹864.43 | 30 K | 04 Sep 2026 - 07 Sep 2026 | Market Sale | 4,25,150 | Insider Trading | — | Equity |
| 31 Aug 2026 | Promoter Group | Disposal | 0.000662 | 0.5 | 5.12 L | ₹853.15 | 600 | 26 Aug 2026 - 27 Aug 2026 | Market Sale | 4,55,150 | Insider Trading | — | Equity |
| 19 Aug 2026 | Promoter Group | Disposal | 0.016542 | 0.5 | 1.32 Cr | ₹878.69 | 15 K | 18 Aug 2026 - 19 Aug 2026 | Market Sale | 4,55,750 | Insider Trading | — | Equity |
| 18 Aug 2026 | Promoter Group | Disposal | 0.011028 | 0.74 | 86.83 L | ₹868.32 | 10 K | 13 Aug 2026 - 14 Aug 2026 | Market Sale | 6,71,754 | Insider Trading | — | Equity |
| 18 Aug 2026 | Promoter Group | Disposal | 0.005514 | 0.73 | 44.09 L | ₹881.79 | 5 K | 17 Aug 2026 - 18 Aug 2026 | Market Sale | 6,66,754 | Insider Trading | — | Equity |
| 18 Aug 2026 | Promoter Group | Disposal | 0.060653 | 0.52 | 4.73 Cr | ₹859.86 | 55 K | 17 Aug 2026 - 18 Aug 2026 | Market Sale | 4,70,750 | Insider Trading | — | Equity |
| 18 Aug 2026 | Promoter Group | Disposal | 0.025896 | 0.58 | 2.07 Cr | ₹881.79 | 23.48 K | 13 Aug 2026 - 14 Aug 2026 | Market Sale | 5,25,750 | Insider Trading | — | Equity |
| 02 Jul 2026 | Promoter Group | Disposal | 0.09734 | 0.6 | 6.03 Cr | ₹682.66 | 88.27 K | 30 Jun 2026 - 01 Jul 2026 | Market Sale | 5,49,232 | Insider Trading | — | Equity |
Aarti Pharmalabs Share Price
885.10+38.65 (+4.57%)
-4.85% past 1 Year
Aarti Pharmalabs Limited (APL) (Formerly known as Aarti Organics Limited) is a leading Indian manufacturer of Pharmaceuticals and Nutraceuticals with a global footprint. The company is an, internationally recognised manufacturer
Corporate Actions
Date
Type
Details
Company details
Aarti Pharmalabs Share Price
885.10+38.65 (+4.57%)
-4.85% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Aarti Pharmalabs Share Price
885.10+38.65 (+4.57%)
-4.85% past 1 Year
News
Block deal in Aarti Pharmalabs on NSE worth Rs 62.93 crores
Equity
AARTIPHARM
Aarti Pharma reports higher first quarter EBITDA and margin expansion
Equity
AARTIPHARM
Aarti Pharma Q1 revenue rises to Rs 536 crores year on year
Equity
AARTIPHARM
Aarti Pharma reports Q1 standalone net profit rises to Rs 76.10 crores
Equity
AARTIPHARM
Aarti Pharmalabs reports lower Q4 profit, revenue rises year on year
Equity
AARTIPHARM
Aarti Pharmalabs Q4 FY Earnings show weaker EBITDA and margin performance YoY
Equity
AARTIPHARM
Aarti Pharma Q4 EBITDA declines year-on-year with margin compression reported
Equity
AARTIPHARM
Aarti Pharma Q4 profit declines sharply amid extraordinary revenue collapse YoY
Equity
AARTIPHARM
Aarti Pharmalabs reports Profit after tax of 62.03 Crores, in the March 2026 quarter
Equity
AARTIPHARM
Aarti Pharmalabs informs about conference call
Equity
AARTIPHARM
Aarti Pharmalabs informs about analyst meet
Equity
AARTIPHARM
Aarti Pharmalabs informs about substantial acquisition of shares & takeovers
Equity
AARTIPHARM
Aarti Pharmalabs informs about disclosure
Equity
AARTIPHARM
Aarti Pharmalabs Receives One Procedural US FDA Form 483 Observation at Tarapur Unit-IV.
Equity
AARTIPHARM
Aarti Pharmalabs informs about disclosures
Equity
AARTIPHARM
Aarti Pharmalabs Reports Minor Chemical Leak at Tarapur Unit-VI, 22 Workers Hospitalised, No Casualties.
Equity
AARTIPHARM
Aarti Pharmalabs informs about transcript of earnings call
Equity
AARTIPHARM
Aarti Pharmalabs Q3 EBITDA Declines to Rs 102 Crores, Margin Slightly Down YoY.
Equity
AARTIPHARM
Aarti Pharmalabs reports Profit after tax of 43.85 Crores, in the December 2025 quarter
Equity
AARTIPHARM
Aarti Pharmalabs Q3FY26 Earnings: Net Profit Down 35% YoY to Rs 48 Cr, Revenue Falls 20% YoY.
Equity
AARTIPHARM